Bone scan and prostatic cancer;Scintigraphie osseuse et cancer de la prostate

Annales d'Urologie

Volumn 34, Issue 4, 2000, Pages 254-265

  Letaief, B ^a   Boughattas, S ^a   Hassine, H ^a   Essabbah, H ^a  

^a Service de Medicine Nucleaire   (France)

Author keywords

Bone scan; Prognostic factors; Prostatic cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; FOLLOW UP; HUMAN; PAIN; PROGNOSIS; PROSTATE CANCER; REVIEW;

BONE AND BONES; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033851102     PISSN: 00034401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Imaging of patients with stage D2 prostatic carcinoma
2. Nuclear bone imaging in metastatic cancer of the prostate
3. Pathologie osteo-articulaire
4. Efficacy of follow-up bone scans in carcinoma of the prostate
5. Some limitations of the radio-isotope bone scan in patients with metastatic prostatic cancer
6. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate
7. Extent of disease based on initial bone scan: Important prognostic predictor for patients with metastasic prostatic cancer
8. The importance of prognostic factors in advanced prostate cancer
9. Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated carcinoma
10. Solitary lesions on bone scan in genito-urinary malignancy
11. Unifocal, bone findings by scintigraphy
12. Solitary abnormalities in bone scans of patients with extra osseous malignancies
13. Diagnostic bone scintigraphy in oncology
14. Clinical significance of solitary rib lesions in patients with extraskeletal malignancy
15. Prediction of radionuclide bone imaging findings by Gleason histologic grading of prostate carcinoma
16. Pathogenetic differentiation of the bone superscan using bone marrow scintigraphy
17. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer
18. Leuprolide therapy for prostate cancer An association with scintigraphic 'flare' on bone scan
19. Clinical significance of routine follow-up examinations in patients with metastatic cancer of the prostate under hormone treatment
20. Systemic treatment of advanced prostatic cancer: Developpement of new systemic for defining response
21. The cellular basis of site-specific tumor metastasis
22. The role of vertebral veins in the dissemination of prostatic carcinoma
23. Distribution of skeletal metastases in prostatic and lung cancer
24. Quantitative radiology for staging and prognosis of patients with advanced prostatic carcinoma
25. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
26. Prognostic factors in disseminated prostatic cancer, with special emphasis on extent of disease
27. When is bone scintigraphy necessary in the assessment of newly diagnosed untreated prostate cancer
28. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer
29. Analysis of prognostic factors in men with metastatic prostate cancer
30. Bone scan as a stratification variable in advanced prostate cancer
31. Pain as an indicator of bone metasasis
32. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters
33. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
34. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate I: Untreated patients
35. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II: Radical prostatectomy treated patients
36. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer
37. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer
38. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
39. Are pelvic computed tomography bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?
40. The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma
41. Using PSA to eliminate the staging radio-nuclide bone scan: Significant economic implications
42. Oncology imaging: Interactions of nuclear medicin with CT and MRI using the bone scan as a model
43. Attitudes of European urologists to early prostatic carcinoma I: Diagnostic work-up on suspected prostatic cancer cases
44. Use of imaging tests for staging newly diagnosed prostate cancer: Trends from the Capsure database
45. Clinical use of prostate-specific antigen in the staging of patients with prostatic carcinoma
46. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy
47. Prostatic adenocarcinoma: Relationship of grade and local extent to the pattern of metastases
48. Value of bone scanning in neoplastic disease
49. Value of preoperative PSA in predicting pathologic stage of patients undergoing salvage prostatectomy
50. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal in patients with adenocarcinoma of the prostate
51. The role of routine follow-up bone scans after definitive therapy of localized prostatic cancer
52. Evaluation and skeletal metastases
53. Skeletal scintigraphy for routine surveillance of MO prostatic carcinoma
54. Current follow-up strategies after radical prostatectomy: A survey of american urological association urologists
55. Follow-up in prostate cancer patients which parameters are necessary?
56. Serum prostate-specific antigen elevation in the post-radical prostatectomy patient
57. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins Experience after 10 years
58. Natural history of progression after PSA elevation following radical prostatectomy
59. Prostate specific antigen and local recurrence after radical prostatectomy
60. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
61. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up
62. PSA and bone scintigraphy
63. PSA after definitive radiotherapy for clinically localized prostate cancer
64. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy
65. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate III: Radiation treated patients
66. Computerised bone scan A potentially useful technique to measure response in prostatic carcinoma
67. Serum PSA after antiandrogen therapy
68. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate
69. Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?